California Institute of Technology

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

Retrieved on: 
Thursday, March 23, 2023

LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

Key Points: 
  • The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
  • This is the first of our presidential appointments and we look forward to providing updates on further appointments in due course."
  • Samson joined Clarivate in October 2020 with the acquisition of CPA Global, having joined CPA Global in 2014 as Chief Operating Officer.
  • Andy Snyder, Chairman of the Board, Clarivate commented: "We look forward to Dr. Saha joining our Board.

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

Retrieved on: 
Thursday, March 23, 2023

LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

Key Points: 
  • The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
  • This is the first of our presidential appointments and we look forward to providing updates on further appointments in due course."
  • Samson joined Clarivate in October 2020 with the acquisition of CPA Global, having joined CPA Global in 2014 as Chief Operating Officer.
  • Andy Snyder, Chairman of the Board, Clarivate commented: "We look forward to Dr. Saha joining our Board.

Novel AI-based Car Dealership Analytics Platform Gives Consumers An Edge

Retrieved on: 
Thursday, March 23, 2023

AUSTIN, Texas, March 23, 2023 /PRNewswire/ -- Topmarq Inc today announced the beta release of a novel car dealership analytics platform that leverages AI and data to improve consumers' search for a new or used vehicle. The service gives potential buyers the ability to find dealers in their area using actionable insights like average vehicle prices, model specialities, and more.

Key Points: 
  • AUSTIN, Texas, March 23, 2023 /PRNewswire/ -- Topmarq Inc today announced the beta release of a novel car dealership analytics platform that leverages AI and data to improve consumers' search for a new or used vehicle.
  • The service gives potential buyers the ability to find dealers in their area using actionable insights like average vehicle prices, model specialities, and more.
  • According to Autotrader, 78% of car shoppers use 3rd party sites to find their future vehicles.
  • Topmarq's new AI-based analytics platform is aimed at solving the workflow for consumers who fall through the cracks with current solutions.

BlueQubit Launches Platform to Simplify Quantum App Development

Retrieved on: 
Wednesday, March 22, 2023

BlueQubit , a San Francisco-based quantum software company, launches a new platform that aims to democratize access to quantum computing.

Key Points: 
  • BlueQubit , a San Francisco-based quantum software company, launches a new platform that aims to democratize access to quantum computing.
  • Traditional quantum computing systems can be complex and difficult to use, making it challenging for developers to create and test quantum algorithms.
  • BlueQubit addresses this issue by providing a user-friendly platform that allows developers and researchers to access and utilize powerful quantum hardware with just one simple click.
  • The BlueQubit platform was developed by Dr. Hrant Gharibyan, a quantum scientist from Caltech, and Hayk Tepanyan, a former ML engineer at Google.

New Jersey Institute of Technology Names John Pelesko Provost and SVP for Academic Affairs

Retrieved on: 
Monday, March 20, 2023

Newark, N.J., March 20, 2023 (GLOBE NEWSWIRE) -- New Jersey Institute of Technology (NJIT) has selected John Pelesko to serve as its next provost and senior vice president for academic affairs after a nationwide search.

Key Points: 
  • Newark, N.J., March 20, 2023 (GLOBE NEWSWIRE) -- New Jersey Institute of Technology (NJIT) has selected John Pelesko to serve as its next provost and senior vice president for academic affairs after a nationwide search.
  • Pelesko, currently the dean of the College of Arts and Sciences at the University of Delaware (UD), will start on Aug. 1.
  • More broadly, he’ll work closely with NJIT President Teik C. Lim and the Board of Trustees to identify, communicate and achieve NJIT’s academic priorities.
  • Before UD, Pelesko taught mathematics at Georgia Institute of Technology and computing and mathematical sciences at California Institute of Technology.

NTT Research Announces Plans to Double the Size of its Optics Lab

Retrieved on: 
Wednesday, March 15, 2023

NTT Research, Inc. , a division of NTT (TYO:9432), today announced plans to double the size of its optical research facility in 2023.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced plans to double the size of its optical research facility in 2023.
  • “We are excited to announce these expansion plans,” PHI Lab Director Yoshihisa Yamamoto said.
  • This hybrid-remote smart workplace, named the NTT OneVision Center, features collaboration-focused spaces, working pods and offices for research staff.
  • It is also conducting joint research with the NASA Ames Research Center in Silicon Valley and 1QBit, a private quantum computing software company.

Cambridge Launches AI Research Ethics Policy

Retrieved on: 
Tuesday, March 14, 2023

The rules are set out in the first AI ethics policy from Cambridge University Press and apply to research papers, books and other scholarly works.

Key Points: 
  • The rules are set out in the first AI ethics policy from Cambridge University Press and apply to research papers, books and other scholarly works.
  • Mandy Hill, Managing Director for Academic at Cambridge University Press & Assessment, said: “Generative AI can enable new avenues of research and experimentation.
  • The Cambridge principles for generative AI in research publishing include that:
    AI use must be declared and clearly explained in publications such as research papers, just as scholars do with other software, tools and methodologies.
  • Each year Cambridge University Press publishes tens of thousands research papers in more than 400 peer-reviewed journals and 1,500 research monographs, reference works and higher education textbooks.

Powered By Proteomics, iuno Launches Personalized Skincare System

Retrieved on: 
Wednesday, March 8, 2023

Today, iuno officially opens their Beta program to the public, providing the chance to experience a truly personalized and evolving beauty routine.

Key Points: 
  • Today, iuno officially opens their Beta program to the public, providing the chance to experience a truly personalized and evolving beauty routine.
  • View the full release here: https://www.businesswire.com/news/home/20230308005149/en/
    Offering a glimpse into the future of skincare, The iuno Protocol utilizes cutting-edge science and technology at every touchpoint.
  • With the public release of its Beta program, iuno invites users to be among the first to experience proteomic skincare.
  • Users can opt in to the personalized skincare regimen and app access after receiving their results for $249.

Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer

Retrieved on: 
Tuesday, March 7, 2023

"Capsida is at a pivotal phase in its evolution," said Peter Anastasiou, Capsida's Chief Executive Officer.

Key Points: 
  • "Capsida is at a pivotal phase in its evolution," said Peter Anastasiou, Capsida's Chief Executive Officer.
  • "Capsida's science is focused on overcoming many of the challenges with first-generation gene therapies, by improving effectiveness and safety.
  • Capsida co-founder Nicholas Flytzanis, Ph.D., will continue to lead the Company's research and platform innovation efforts as Chief Research and Innovation Officer.
  • Co-founder Nick Goeden, Ph.D., will continue to lead Capsida's technology development efforts and serve as the research lead for partnerships as Chief Technology Officer.

Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

Retrieved on: 
Wednesday, March 1, 2023

BOSTON and LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of Patrick Yue, MD, to Centessa’s management team as Senior Vice President of Clinical Development, Innovative Medicines.

Key Points: 
  • BOSTON and LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of Patrick Yue, MD, to Centessa’s management team as Senior Vice President of Clinical Development, Innovative Medicines.
  • “Patrick is a physician-scientist who brings extensive clinical development experience to this newly created position at Centessa.
  • Prior to joining Centessa, Dr. Yue was Vice President of Clinical Science at Global Blood Therapeutics, where he oversaw four development programs, including voxelotor (Oxbryta) a treatment for sickle cell disease.
  • Dr. Yue has spent 12 years in the biotech/pharmaceutical industry, taking on roles of increasing responsibility at Gilead, Portola, Alexion and Pfizer.